SCHEMBL25228282

SCHEMBL25228282

CC1(NC(=O)Cc2ccccc2)CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 3/20 0.56
▸ OPRD1 P41143 1/20 0.51
▸ OPRK1 P41145 1/20 0.51
▸ ANO1 Q5XXA6 1/20 0.51
▸ STS P08842 1/20 0.48
▸ KDM4E B2RXH2 1/20 0.48
▸ PKM P14618 1/20 0.48
▸ ACHE P22303 1/20 0.47
▸ TSHR P16473 2/20 0.47
▸ ALOX15 P16050 1/20 0.47
▸ ATM Q13315 1/20 0.47
▸ TACR1 P25103 1/20 0.46
▸ HDAC1 Q13547 1/20 0.46
▸ HDAC8 Q9BY41 1/20 0.46
▸ HDAC6 Q9UBN7 1/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ KEAP1 Q14145 1/20 0.44
▸ NFE2L2 Q16236 1/20 0.44
▸ GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28664079 0.87 MAPT (0.53) GPR119ANO1STSSMN1; SMN2
SCHEMBL551650 0.84 MEN1 (0.48) OPRD1OPRK1STSKDM4EPKM
SCHEMBL27742618 0.80 GPR119 (0.49) GPR119OPRD1OPRK1STSKDM4E
SCHEMBL20068820 0.79 NPC1 (0.51) KDM4EHDAC8HDAC6MEN1KMT2A
SCHEMBL1959327 0.79 MEN1 (0.44) OPRD1OPRK1ANO1STSKDM4E
SCHEMBL7507956 0.79 MEN1 (0.49) OPRD1OPRK1KDM4ETACR1HDAC1
SCHEMBL5849307 0.79 GPR119 (0.59) GPR119STSKDM4EPKMACHE
SCHEMBL17033023 0.79 MEN1 (0.53) KDM4EHDAC8HDAC6MEN1KMT2A
SCHEMBL12203692 0.79 OPRD1 (0.53) GPR119OPRD1OPRK1STSKDM4E
SCHEMBL15796942 0.77 MEN1 (0.44) OPRD1OPRK1STSKDM4EPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230233692-A1 COMPOUNDS FOR TARGETED DEGRADATION OF RET C4 THERAPEUTICS, INC. (US) 2023-07-27 — — US disclosed
US-20230233692-A1 COMPOUNDS FOR TARGETED DEGRADATION OF RET C4 THERAPEUTICS, INC. (US) 2023-07-27 — — US disclosed
CN-116490186-A Compounds for targeted degradation of RET C4医药公司 2023-07-25 — — CN disclosed
EP-4192458-A1 COMPOUNDS FOR TARGETED DEGRADATION OF RET C4 Therapeutics, Inc. (US) 2023-06-14 — — EP disclosed
WO-2022032026-A1 COMPOUNDS FOR TARGETED DEGRADATION OF RET C4 THERAPEUTICS, INC. (US) 2022-02-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230233692-A1 COMPOUNDS FOR TARGETED DEGRADATION OF RET RET, HRAS, RBX1 GPR119 3419/4885OPRD1 3168/4885OPRK1 3175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback